Last reviewed · How we verify
FluCAM [Fludara + Campath]
FluCAM combines a purine nucleoside analog that inhibits DNA synthesis with a monoclonal antibody that depletes lymphocytes, providing dual immunosuppressive and cytotoxic activity.
FluCAM combines a purine nucleoside analog that inhibits DNA synthesis with a monoclonal antibody that depletes lymphocytes, providing dual immunosuppressive and cytotoxic activity. Used for Chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma.
At a glance
| Generic name | FluCAM [Fludara + Campath] |
|---|---|
| Also known as | alemtuzumab, fludarabine phosphate, Fludara, Campath |
| Sponsor | Genzyme, a Sanofi Company |
| Drug class | Combination chemotherapy and monoclonal antibody |
| Target | Ribonucleotide reductase / DNA polymerase (fludarabine); CD52 (alemtuzumab) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Fludara (fludarabine) is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to apoptosis of lymphoid cells. Campath (alemtuzumab) is a humanized monoclonal antibody targeting CD52 on lymphocytes, causing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The combination provides enhanced lymphocyte depletion for treating hematologic malignancies.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- B-cell non-Hodgkin lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Infusion reactions
- Immunosuppression
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluCAM [Fludara + Campath] CI brief — competitive landscape report
- FluCAM [Fludara + Campath] updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI